# Mirvetuximab Soravtansine: First Approval

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/mirvetuximab-soravtansine-first-approval/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Young‐A Heo |
| Citations | 110 |
| DOI | 10.1007/s40265-023-01834-3 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://figshare.com/articles/online_resource/Mirvetuximab_Soravtansine_First_Approval/21788783 |
| OpenAlex ID | https://openalex.org/W4317435892 |
| PMID | 36656533 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Young‐A Heo](https://scholariq.org/researchers/young-a-heo/)

## Paper journal

- [Drugs](https://scholariq.org/journals/drugs/)

## Paper primary topic

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)

## Paper topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.